Last Updated: September 24, 2026

SDAMLO Drug Patent Profile

Name: SDAMLO Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Sdamlo, and when can generic versions of Sdamlo launch?

Sdamlo is a drug marketed by Brillian Pharma and is included in one NDA.

The generic ingredient in SDAMLO is amlodipine besylate. There is one drug master file entry for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the amlodipine besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sdamlo

A generic version of SDAMLO was approved as amlodipine besylate by COREPHARMA on May 23^rd, 2007.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for SDAMLO?
What are the global sales for SDAMLO?
What is Average Wholesale Price for SDAMLO?

Summary for SDAMLO

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in SDAMLO?	SDAMLO excipients list
DailyMed Link:	SDAMLO at DailyMed

Drug patent expirations by year for SDAMLO

Pharmacology for SDAMLO

Drug Class	Calcium Channel Blocker Dihydropyridine Calcium Channel Blocker
Mechanism of Action	Calcium Channel Antagonists Cytochrome P450 3A Inhibitors

US Patents and Regulatory Information for SDAMLO

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Brillian Pharma	SDAMLO	amlodipine besylate	FOR SOLUTION;ORAL	219531-001	Jul 24, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Brillian Pharma	SDAMLO	amlodipine besylate	FOR SOLUTION;ORAL	219531-002	Jul 24, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Brillian Pharma	SDAMLO	amlodipine besylate	FOR SOLUTION;ORAL	219531-003	Jul 24, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.